Tom Hardy is giving James Bond 007 a run for his money at the box office, as Venom 2 and No Time To Die both hit big.
For much of the spring and summer, multiplexes were looking to the return of James Bond to reignite blockbuster cinema. As it turned out, whilst that hope wasn’t forlorn, the emphasis should perhaps equally have been on the Venom sequel.
No Time To Die has a high bar to profitability, with some $900m in box office takings required to send it into the green. It’s running just a little behind the performance of Spectre and Skyfall at the moment, but it’s still doing pretty decent business. The film has quickly found its way to a global box office take of $447m so far, and still has a fair few places it hasn’t yet opened. Whilst it’s likely to fall a little short of $900m, it won’t be by much.
The juggernaut of the year though now looks like being the Tom Hardy-headlined Venom: Let There Be Carnage. The sequel – that Sony briefly considered pushing into next year when it looked like audiences were still staying away from cinemas – has gone nuclear at the box office. In America alone it’s standing at $168m of business. Add in takings from around the planet, and that total is at $283m, with – again – a fair few places left to open.
There’s a strong possibility that Venom may now outgross 007. In truth, though, the levels of business done by both films is a massive breathe out moment for multiplexes…
More as we hear it…
—
Thank you for visiting! If you’d like to support our attempts to make a non-clickbaity movie website:
Follow Film Stories on Twitter here, and on Facebook here.
Buy our Film Stories and Film Stories Junior print magazines here.
Become a Patron here.
